Analytical Data
-
Gene name
Calcitonin/CALCA
-
简介
Calcitonin/CALCA protein acts as a vasodilator, dilating different blood vessels, including coronary, cerebral, and systemic vessels. Its presence in the central nervous system suggests its potential role as a neurotransmitter or neuromodulator. Calcitonin/CALCA Protein, Human (P. pastoris, His-SUMO) is the recombinant human-derived Calcitonin/CALCA protein, expressed by P. pastoris , with N-SUMO, N-6*His labeled tag.
- Application
-
Alternative Names
CALCA; CALC1Calcitonin gene-related peptide 1; Alpha-type CGRP; Calcitonin gene-related peptide I; CGRP-I
-
Species
Human
-
Source
P. pastoris
-
Tag
N-SUMO;N-6*His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P06881
-
Expression Region
A83-F119
-
Protein Length
Full Length of Mature Peptide
-
Molecular Weight
22 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Calcitonin, a peptide hormone produced by the parafollicular cells of the thyroid gland, plays a crucial role in calcium homeostasis, primarily by inhibiting osteoclast activity and reducing bone resorption. The discovery of the CALCA gene, which encodes calcitonin and its related peptides, has spurred interest in understanding its biological functions and therapeutic potential. Research has demonstrated that calcitonin can be beneficial in treating osteoporosis and related bone disorders by decreasing the risk of fractures. Furthermore, its analgesic properties have garnered attention for potential applications in pain management, particularly in conditions such as arthritis and certain cancer-related pain. The recombinant production of calcitonin and CALCA-derived proteins allows for detailed study and potential clinical applications. These recombinant proteins offer advantages in terms of purity, consistency, and scalability, facilitating research into their mechanisms of action and efficacy. As scientists explore the multifaceted roles of calcitonin, including its interactions with other signaling pathways and cellular processes, the development of novel therapeutic strategies is on the horizon, harnessing the potential benefits of this hormone in regenerative medicine and orthopedic treatments.
